

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

# Combination Therapy for the Treatment of Central Nervous System Malignancies: Clinical Effectiveness and Guidelines

Service Line: Rapid Response Service  
Version: 1.0  
Publication Date: February 08, 2019  
Report Length: 7 Pages

**Authors:** Deba Hafizi, Aleksandra Grobelna

**Cite As:** Combination therapy for the treatment of central nervous system malignancies: clinical effectiveness and guidelines. Ottawa: CADTH; 2019 Feb. (CADTH rapid response report: summary of abstracts).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

## Research Questions

1. What is the clinical effectiveness of combination therapy for the treatment of patients with central nervous system malignancies?
2. What are the evidence-based guidelines associated with the use of combination therapy for the treatment of patients with central nervous system malignancies?

## Key Findings

Three non-randomized studies were identified regarding combination therapy for the treatment of central nervous system malignancies.

## Methods

A limited literature search was conducted on key resources including PubMed, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2014 and January 25, 2019. Internet links were provided, where available.

## Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

**Table 1: Selection Criteria**

<b>Population</b>	Patients (adults and children) with a CNS malignancy (e.g., gliomatosis cerebri, meningioma, glioblastoma, glioma, astrocytoma, neuroblastoma)
<b>Intervention</b>	Either combined with each other (in groups of two or more) or with standard of care (e.g., conventional chemotherapy). <ul style="list-style-type: none"> <li>• Dimethyl sulfoxide (DMSO);</li> <li>• Hyperthermia (any variant, including electric and magnetic);</li> <li>• Sonodynamic therapy;</li> <li>• Laser therapy;</li> <li>• Rife therapy;</li> <li>• Biomagnetic therapy</li> </ul>
<b>Comparator</b>	Q1: Any comparator; No comparator Q2: No comparator
<b>Outcomes</b>	Q1: Clinical effectiveness (e.g., progression-free survival, response rate, change in tumour size, overall survival, quality of life) and safety (e.g., toxicity, adverse events, discontinuation) Q2: Guidelines
<b>Study Designs</b>	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based guidelines

## Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

Three non-randomized studies were identified regarding combination therapies for central nervous system malignancies. No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, or evidence-based guidelines were identified.

Additional references of potential interest are provided in the appendix.

## Overall Summary of Findings

Three non-randomized studies were identified regarding combination therapies for central nervous system (CNS) malignancies.<sup>1-3</sup> Each study utilized a varying combination of therapies for CNS cancers. The authors of the first study investigated the safety of using radiation and laser therapy in patients with brain tumours.<sup>1</sup> They observed that laser interstitial thermal therapy in combination with radiation therapy can induce cerebral edema (a safety issue) and thus prolong cancer treatment.<sup>1</sup> In a minority of cases, patients may require more aggressive treatment such as drug therapy.<sup>1</sup> The authors of the second study<sup>2</sup> investigated the efficacy of radiation therapy with hyperthermia for patients with high grade gliomas and observed that combination therapy of radiation and hyperthermia was safe and well-tolerated. In the third study<sup>3</sup> the authors investigated the efficacy and cost-effectiveness of modulated electrohyperthermia in combination with chemotherapy treatment. Their effect-to-treatment analysis found that patient survival significantly improved after receiving the combination therapy in a regimen of 21 out of 28 days.<sup>3</sup>

No evidence-based guidelines were identified; therefore, no summary can be provided.

## References Summarized

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

No literature identified.

### Randomized Controlled Trials

No literature identified.

## Non-Randomized Studies

### *Radiation and Laser Therapy*

1. Maraka S, Asmaro K, Walbert T, Lee I. Cerebral edema induced by laser interstitial thermal therapy and radiotherapy in close succession in patients with brain tumor. *Lasers Surg Med.* 2018 Sep;50(9):917-923.  
[PubMed: PM29799137](#)

### *Radiation and Hyperthermia*

2. Heo J, Kim SH, Oh YT, Chun M, Noh OK. Concurrent hyperthermia and re-irradiation for recurrent high-grade gliomas. *Neoplasma.* 2017;64(5):803-808.  
[PubMed: PM28592133](#)

### *Chemotherapy and Hyperthermia*

3. Roussakow SV. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. *BMJ open.* 2017 Nov 3;7(11):e017387.  
[PubMed: PM29102988](#)

## Guidelines and Recommendations

No literature identified.

## Appendix — Further Information

### Previous CADTH Reports

4. Alternating electric fields (“tumour-treating fields”) for the treatment of glioblastoma. (*CADTH issues in emerging health technologies; issue 165*). Ottawa (ON): CADTH; 2018: <https://www.cadth.ca/dv/ieht/alternating-electric-fields-tumour-treating-fields-treatment-glioblastoma>. Accessed 2019 Feb 6.

### Non-Randomized Studies

#### *Radiation and Hyperthermia*

##### **Case Series**

5. Grauer O, Jaber M, Hess K, et al. Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients. *J Neurooncol*. 2019 Jan;141(1):83-94. [PubMed: PM30506500](https://pubmed.ncbi.nlm.nih.gov/30506500/)

#### *Chemotherapy and Laser Therapy*

##### **Case Series**

6. Ali SC, Basil GW, Diaz RJ, Komotar RJ. The safety of bevacizumab administered shortly after laser interstitial thermal therapy in glioblastoma: a case series. *World Neurosurg*. 2018 Sep;117:e588-e594. [PubMed: PM29933086](https://pubmed.ncbi.nlm.nih.gov/29933086/)

#### *High Intensity Focused Ultrasound – Uncertain if Combined with Another Therapy*

##### **Alternative Population – Mixture of Cancer Types**

7. Shim J, Staruch RM, Koral K, Xie XJ, Chopra R, Laetsch TW. Pediatric sarcomas are targetable by MR-guided high intensity focused ultrasound (MR-HIFU): anatomical distribution and radiological characteristics. *Pediatr Blood Cancer*. 2016 Oct;63(10):1753-1760. [PubMed: PM27199087](https://pubmed.ncbi.nlm.nih.gov/27199087/)

#### *Alternative Outcome*

8. Leuthardt EC, Duan C, Kim MJ, et al. Hyperthermic laser ablation of recurrent glioblastoma leads to temporary disruption of the peritumoral blood brain barrier. *PLoS One*. 2016;11(2):e0148613. [PubMed: PM26910903](https://pubmed.ncbi.nlm.nih.gov/26910903/)

### Review Articles

9. Paolillo M, Boselli C, Schinelli S. Glioblastoma under siege: an overview of current therapeutic strategies. *Brain Sci*. 2018;8(1). <https://www.mdpi.com/2076-3425/8/1/15/htm>. Accessed 2019 Feb

10. Mahmoudi K, Bouras A, Bozec D, Ivkov R, Hadjipanayis C. Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans. *Int J Hyperthermia*. 2018 Dec;34(8):1316-1328.  
[PubMed: PM29353516](#)
11. Borasi G, Nahum A. A new glioblastoma treatment, potentially highly effective, combining focused ultrasound generated hyperthermia and radiations. *JSM Brain Sci*. 2017;2(1).  
<https://pdfs.semanticscholar.org/0b6b/da66b13491284fc21f2ad5715f7dc4573031.pdf>  
Accessed 2019 Feb 6
12. Wang X, Jia Y, Wang P, Liu Q, Zheng H. Current status and future perspectives of sonodynamic therapy in glioma treatment. *Ultrason Sonochem*. 2017 Jul;37:592-599.  
[PubMed: PM28427672](#)
13. Bredlau AL, McCrackin MA, Motamarry A, et al. Thermal therapy approaches for treatment of brain tumors in animals and humans. *Crit Rev Biomed Eng*. 2016;44(6):443-457.  
[PubMed: PM29431091](#)
14. Lee Titsworth W, Murad GJ, Hoh BL, Rahman M. Fighting fire with fire: the revival of thermotherapy for gliomas. *Anticancer Res*. 2014 Feb;34(2):565-574.  
[PubMed: PM24510985](#)

## Additional References

### *Laser Therapy – Uncertain if Combined with Another Therapy Modality*

15. Mohammadi AM, Schroeder JL. Laser interstitial thermal therapy in treatment of brain tumors--the NeuroBlate System. *Expert Rev Med Devices*. 2014 Mar;11(2):109-119.  
[PubMed: PM24471476](#)

### *Radiation and Hyperthermia*

#### **Mathematical Models**

16. Borasi G, Nahum A, Paulides MM, et al. Fast and high temperature hyperthermia coupled with radiotherapy as a possible new treatment for glioblastoma. *Journal of therapeutic ultrasound*. 2016;4:32.  
[PubMed: PM27980785](#)